{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Graft Vs Host Disease",
            "NStudiesAvail": 430108,
            "NStudiesFound": 60,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 60,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Li Yu, Dr"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Complete remission, partial remission, disease progression"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Disease-related clinical reactions"
                        ],
                        "NCTId": [
                              "NCT05152160"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Vikram Mathews, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Control of GVHD"
                        ],
                        "NCTId": [
                              "NCT00314483"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Consuelo del Ca\u00f1izo, MD",
                              "Jos\u00e9 A P\u00e9rez-Sim\u00f3n, MD",
                              "David Varc\u00e1rcel Ferrer\u00edas, MD",
                              "Carmen Mart\u00ednez Mu\u00f1oz, MD",
                              "Jos\u00e9 Rif\u00f3n Roca, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Determine the safety/efficacy of expanded in-vitro allogenic mesenchymal stem cell infusion in patients developing a GVHD refractory to the usual therapeutic measures after undergoing an allogeneic hematopoietic stem cell transplant.",
                              "Efficacy will be evaluated in terms of GVHD response.",
                              "Safety will be evaluated in terms of incidence of adverse events and toxicities related to the administration of MSC."
                        ],
                        "NCTId": [
                              "NCT00447460"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Lucia S Silla"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Complete response: disappearance of all symptoms"
                        ],
                        "NCTId": [
                              "NCT02770430"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Ferm\u00edn M S\u00e1nchez Guijo, MD",
                              "Felipe Prosper, MD",
                              "Eduardo Olavarr\u00eda, MD",
                              "Roc\u00edo Parody, MD",
                              "Carmen Regidor, MD",
                              "Carmen Mart\u00ednez, MD",
                              "Rodrigo Martino, MD",
                              "Jos\u00e9 Antonio P\u00e9rez-Sim\u00f3n, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Infusion related.\nInfection Rate."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse effects"
                        ],
                        "NCTId": [
                              "NCT01956903"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Qifa Liu"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The response criteria include complete response (CR), part response (PR), stable disease(SD) and progressive disease(PD). CR:aGVHD symptoms and signs disappear; PR:aGVHD symptoms and signs improve; SD:aGVHD symptoms and signs remain (without improvement or deterioration);PD: aGVHD symptoms and signs deteriorate."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The efficacy of treatment for refractory aGVHD"
                        ],
                        "NCTId": [
                              "NCT01765634"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Qifa Liu"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The response criteria include complete response (CR), part response (PR), stable disease(SD) and progressive disease(PD). CR:cGVHD symptoms and signs disappear; PR:cGVHD symptoms and signs improve; SD:cGVHD symptoms and signs remain (without improvement or deterioration);PD: cGVHD symptoms and signs deteriorate."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The efficacy of treatment for refractory cGVHD"
                        ],
                        "NCTId": [
                              "NCT01765660"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Christopher James, PA"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 28, 2006"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)",
                              "Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal\u00ae in the preceding study (Protocol No. 260)."
                        ],
                        "NCTId": [
                              "NCT00136903"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "He Huang, MD",
                              "Chunhua Zhao, MD,PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The total Response rate defined as patients with complete and partial response"
                        ],
                        "NCTId": [
                              "NCT01526850"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Xin Du, MD.PhD."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The total Response rate defined as patients with complete and partial response."
                        ],
                        "NCTId": [
                              "NCT00972660"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "SunUk Song, Ph.D.",
                              "Charles, JH Kim, Ph.D.",
                              "Hyun Gyu Lee, M.D.,Ph.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Director",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Aderse Events were record relationship with Investigational Product\n\nNot related\nUnlikely\nPossible\nProbable\nHigh probable\n\nThe severity of adverse events were graded refer to CTCAE (Common Terminology Criteria for Adverse Events) Ver.4.0"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To evaluate number of paticipants with adverse events"
                        ],
                        "NCTId": [
                              "NCT01318330"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Hillard M. Lazarus, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Safety"
                        ],
                        "NCTId": [
                              "NCT00361049"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Manuel Jurado Chac\u00f3n, MD",
                              "Ildefonso Espigado, MD",
                              "Carlos Solano Vercet, MD",
                              "Sebasti\u00e1n Garz\u00f3n L\u00f3pez., MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of adverse events"
                        ],
                        "NCTId": [
                              "NCT01222039"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Katarina Le Blanc, Professor",
                              "Karin Garming-Legert, DDS, PhD",
                              "Rachael Sugars, BSc, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Change in disease activity according to National Institutes of Health criteria for oral graft-versus-host disease"
                        ],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Kilian Kelly, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 28, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety",
                              "Safety"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence and severity of treatment emergent adverse events [safety and tolerability]",
                              "Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]"
                        ],
                        "NCTId": [
                              "NCT02923375"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Frederic Baron, MD, PhD",
                              "Yves Beguin, MD, PhD",
                              "Chantal Lechanteur, PhD",
                              "Etienne Baudoux, MD",
                              "Evelyne Willems, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Study Chair",
                              "Study Chair",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Day-100 incidence of non-relapse mortality"
                        ],
                        "NCTId": [
                              "NCT00504803"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Vital sign\nPhysical examination\nECOG performance status\nMixed Lymphocyte Reaction(MLR)\nAdverse effects related to infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of UCB-MSC in SR-GVHD"
                        ],
                        "NCTId": [
                              "NCT01549665"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Elena Parovichnikova, Prof MD PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "GVHD"
                        ],
                        "NCTId": [
                              "NCT01941394"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Qi-fa Liu, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Overall response rate \uff08ORR\uff09includes complete response (CR) and part response (PR)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "ORR"
                        ],
                        "NCTId": [
                              "NCT04692376"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Christopher James, PA"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 26, 2008"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "A complete response was defined as complete resolution of all clinical signs of Graft versus host disease (GVHD)- that had to be maintained for at least 28 consecutive days (durable complete response [DCR]) within 100 days post first infusion."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration"
                        ],
                        "NCTId": [
                              "NCT00366145"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Sawa Ito, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "itos3@upmc.edu"
                        ],
                        "PointOfContactOrganization": [
                              "NHLBI, NIH"
                        ],
                        "PointOfContactPhone": [
                              "301-326-5233"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Sawa Ito, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "December 13, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The number of subjects without a treatment related severe adverse event (TRSAE) within 56 days of treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Proportion of Subjects Without a Treatment Related Severe Adverse Event"
                        ],
                        "NCTId": [
                              "NCT02379442"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Parvez Ahmed, FCPS, MCPS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be evaluated by reporting any incidence of adverse event, complication and toxicity related to administration of MSCs within 4 weeks of last infusion .",
                              "Efficacy of ex-vivo expanded allogenic mesenchymal stem cell infusion will be determined by organ-specific re-staging and global grading of Acute GVHD as per consensus group criteria. Response will be measured as complete response (CR), partial response (PR), stable disease(SD) and progressive disease(PD). CR:acute GVHD symptoms and signs disappear; PR:aGVHD symptoms and signs improve; SD:aGVHD symptoms and signs remain (without improvement or deterioration);PD: aGVHD symptoms and signs deteriorate.",
                              "Organ-specific scoring and global scoring of chronic GVHD will be done as per NIH consensus criteria of 2014. Treatment response will be measured as complete response (CR), partial response (PR), stable disease(SD) and progressive disease(PD). CR:chronic GVHD symptoms and signs disappear; PR:cGVHD symptoms and signs improve; SD:cGVHD symptoms and signs remain (without improvement or deterioration);PD: cGVHD symptoms and signs deteriorate."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]",
                              "Acute GVHD-restaging [Efficacy]",
                              "Chronic GVHD-restaging [Efficacy]"
                        ],
                        "NCTId": [
                              "NCT02824653"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Erlie Jiang"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) according to aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy"
                        ],
                        "NCTId": [
                              "NCT05531266"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "Prof. Igor B Resnick, MD, PhD, DSci"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "GVHD re-staging and/or GVHD mortality ,side effects"
                        ],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Joseph McGuirk, DO"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "TRSAE is defined as a serious adverse event (SAE) that has a \"probable\" or \"definite\" relation to the MSCTC-0010 infusion. This study will use the descriptions and grading scales from Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) for hematologic and non-hematologic toxicities."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "proportion of participants who have a TRSAE after infusion of MSCTC 0010"
                        ],
                        "NCTId": [
                              "NCT03158896"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [
                              "Yves Beguin, MD, PhD",
                              "Fr\u00e9d\u00e9ric Baron, MD, PhD",
                              "Johan Maertens, MD",
                              "Harry Schouten, MD",
                              "Pierre Zach\u00e9e, MD",
                              "Zwi Berneman, MD",
                              "Lucien Noens, MD, PhD",
                              "Rick Schots, MD, PhD",
                              "Dominik Selleslag, MD",
                              "Augustin Ferrant, MD, PhD",
                              "Chantal Doyen, MD",
                              "Nicole Straetmans, MD",
                              "Nicole Ferster, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.",
                              "Arm 2. Efficacy of MSC infusion as treatment for poor graft function",
                              "Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT"
                        ],
                        "NCTId": [
                              "NCT00603330"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Hu Chen, M.D., Ph.D.",
                              "Bin Zhang, M.D. Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "vital signs\nadverse events related to infusion\nphysical examination indexes\nEastern Cooperative Oncology Group(ECOG)performance status\nmixed lymphocyte reaction(MLR)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of UC-MSC in patients with acute graft-versus-host disease"
                        ],
                        "NCTId": [
                              "NCT01754454"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Qifa Liu, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The responses to aGVHD are according to the literature criteria, including completely response (CR), partial response (PR) and no response (NR), and CR is defined as resolution of all symptoms of aGVHD; PR is defined as a decrease by at least 1 GVHD stage in any 1 organ system without deterioration in others 24. Overall response (OR) includes CR and PR."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The efficacy of treatment for steroid-resistant aGVHD"
                        ],
                        "NCTId": [
                              "NCT02241018"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [
                              "Mahboob Rahman, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "No longer available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT00826046"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Mahboob Rahman"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "No longer available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT00759018"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [
                              "Sen Mui Tan"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Rate of Complete Response (CR) at Day 28",
                              "Rate of Partial Response (PR) at Day 28",
                              "Rate of PR and CR at Day 14",
                              "Percentage of patient requiring MMF rescue during treatment",
                              "Rate of long term complication incidence",
                              "Rate of chronic clinical response incidence"
                        ],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT"
                        ],
                        "NCTId": [
                              "NCT05167188"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Ettore Biagi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Any toxic effect reported during MSCs infusion or in the subsequent 10 days by clinical monitoring",
                              "Feasibility as the possibility of producing adequate lots of patient dedicated MSCs for any patients presenting with steroid resistant GVHD"
                        ],
                        "NCTId": [
                              "NCT01764100"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [
                              "Christopher James, PA"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 25, 2006"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Response by Day 28"
                        ],
                        "NCTId": [
                              "NCT00284986"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [
                              "Xiaohui Zhang, doctor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Complete remission of aGVHD related symptoms and indicators"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Rate of complete remission"
                        ],
                        "NCTId": [
                              "NCT04738981"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [
                              "Molly Gallogly, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Response to therapy:\n\nComplete Remission (CR): Defined as the complete resolution of aGVHD symptoms in all organs, without secondary GVHD therapy.\n\nPartial Remission (PR): Defined as improvement in GVHD stage in all initial GVHD target organs without complete resolution and without worsening in any other GVHD target organs, without secondary GVHD therapy.\n\nThe true response rate will be estimated based on the number of responses using a binomial distribution and its confidence interval will be estimated using Wilson's method"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percent of participants with response to therapy"
                        ],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [
                              "Nico M Wulffraat",
                              "Jurgen H Kuball, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "number of adverse events after infusion of MSC (hPPL)",
                              "Number of severe infections after MSC infusion"
                        ],
                        "NCTId": [
                              "NCT00827398"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation"
                        ],
                        "NCTId": [
                              "NCT03106662"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OverallOfficialName": [
                              "Xin Du, Prof."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Proportion of patients responding to treatment of cGvHD with MSC"
                        ],
                        "NCTId": [
                              "NCT02291770"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OverallOfficialName": [
                              "Duncan Purtill, MB, BS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Survival at one year after onset of graft versus host disease"
                        ],
                        "NCTId": [
                              "NCT01589549"
                        ]
                  },
                  {
                        "Rank": 41,
                        "OverallOfficialName": [
                              "Hong Hoe Koo, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate"
                        ],
                        "NCTId": [
                              "NCT00823316"
                        ]
                  },
                  {
                        "Rank": 42,
                        "OverallOfficialName": [
                              "Xialin Liu, Prof."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 18, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The OSDI is a 12-question validated questionnaire used to measure dry eye symptoms. The OSDI scoring scale ranges from 0 to 100. The lower the score, the more symptomatic relief from dry eye symptoms a patient experiences. Baseline-adjusted scores were tabulated; a decrease over 10 scores from baseline indicates an improvement."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes in Ocular Surface Disease Index (OSDI) Score"
                        ],
                        "NCTId": [
                              "NCT04213248"
                        ]
                  },
                  {
                        "Rank": 43,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "complete and partial response rate"
                        ],
                        "NCTId": [
                              "NCT03631589"
                        ]
                  },
                  {
                        "Rank": 44,
                        "OverallOfficialName": [
                              "Teresa Caballero, Hematologist"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be measured in terms of:\n\nIncidence of Serious Adverse Events after at the time of the infusion of study drug or during follow-up."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety measured by incidence of serious adverse events"
                        ],
                        "NCTId": [
                              "NCT02687646"
                        ]
                  },
                  {
                        "Rank": 45,
                        "OverallOfficialName": [
                              "james Q Yin, M.D.,Ph.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Absolute neutrophil count > 0.5 X 109/l and Platelet count > 20 X 109 /l without infusion of platelet for 7 days."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Engraftment at 42 days post AD-HSC transplantation for patients with severe aplastic anemia."
                        ],
                        "NCTId": [
                              "NCT02407470"
                        ]
                  },
                  {
                        "Rank": 46,
                        "OverallOfficialName": [
                              "Malte von Bonin, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Changes in the amount of mesenchymal stromal cells after allogeneic hematopoietic stem cell transplantation"
                        ],
                        "NCTId": [
                              "NCT02829216"
                        ]
                  },
                  {
                        "Rank": 47,
                        "OverallOfficialName": [
                              "Sagar Munjal"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 10, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "OSSM-001 related safety events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety events"
                        ],
                        "NCTId": [
                              "NCT05443464"
                        ]
                  },
                  {
                        "Rank": 48,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). Response is defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014) and must occur, in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death. CR: Resolution of all manifestations in each organ or site. PR: Improvement in at least 1 organ or site without progression in any other organ or site. cGVHD Progression: Clinically meaningful worsening in 1 or more organs regardless of improvement in other organs."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])"
                        ],
                        "NCTId": [
                              "NCT04189432"
                        ]
                  },
                  {
                        "Rank": 49,
                        "OverallOfficialName": [
                              "Amanda Olson"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of composite serious adverse events (Phase I)",
                              "Patients alive without grade 3, 4 infusional toxicity (Phase II)",
                              "Patients alive with grade 3 or 4 infusional toxicity (Phase II)",
                              "Patients not alive (Phase II)"
                        ],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 50,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence rate of acute rejection and early liver function recovery"
                        ],
                        "NCTId": [
                              "NCT01690247"
                        ]
                  },
                  {
                        "Rank": 51,
                        "OverallOfficialName": [
                              "Patrizio Bollero, Dentistry"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 1, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Healing of oral lesions"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Complete Oral Mucositis Healing"
                        ],
                        "NCTId": [
                              "NCT05018754"
                        ]
                  },
                  {
                        "Rank": 52,
                        "OverallOfficialName": [
                              "Yves Beguin, MD, PhD",
                              "Fr\u00e9d\u00e9ric Baron, MD, PhD",
                              "Evelyne Willems, MD",
                              "Dominik Selleslag, MD, PhD",
                              "Pierre Zach\u00e9e, MD, PhD",
                              "Philippe Lewalle, MD, PhD",
                              "Dominique Bron, MD, PhD",
                              "Wilfried Schroyens, MD, PhD",
                              "Chantal Lechanteur, PhD",
                              "Etienne Baudoux, MD",
                              "Johan Maertens, MD",
                              "Rik Schots, MD, PhD",
                              "Augustin Ferrant, MD, PhD",
                              "Lucien Noens, MD, PhD",
                              "Chantal Doyen, MD, PhD",
                              "Tessa Kerre, MD, PhD",
                              "Carlos Graux, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "One-year overall survival in the 2 arms."
                        ],
                        "NCTId": [
                              "NCT01045382"
                        ]
                  },
                  {
                        "Rank": 53,
                        "OverallOfficialName": [
                              "Christopher James, PA"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 14, 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Treatment was considered a success if all of the following conditions were met: Achieved induction of a complete response (CR) within 28 days after first infusion; CR followed by 28 days maintenance of a clinically meaningful response defined as the response that did not require an increase in corticosteroid dose (methylprednisolone doses >2 milligram/kilogram/day [mg/kg/d] or prednisone doses >2.5 mg/kg/d) for more than 7 consecutive days; Did not require second line/escalation therapy through Study Day 56; and survived 90 study days."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percentage of Participants with Treatment Success"
                        ],
                        "NCTId": [
                              "NCT00562497"
                        ]
                  },
                  {
                        "Rank": 54,
                        "OverallOfficialName": [
                              "Qifa Liu, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Hematopoietic reconstitution post-transplantation is defined as reconstitution of both neutrophil and platelet numbers. Neutrophil reconstitution is defined as occurring on the first 3 consecutive days with an neutrophil(NEU)>0.5\u00d710^9/L, and platelet (PLT) reconstitution is defined as the first >20\u00d710^9/L for 3 consecutive days."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percentage of Participants with Hematopoietic Recovery"
                        ],
                        "NCTId": [
                              "NCT02240992"
                        ]
                  },
                  {
                        "Rank": 55,
                        "OverallOfficialName": [
                              "Guoping Lu, Doctor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The death rate of children in 28 days after their discharged from PICU",
                              "The Marshall Multiple Organ Dysfunction Score (MODS) assesses the same six organ systems using slightly different values for four grades of organ dysfunction. The total score, ranging from 0 to 24, arises from the sum of all single organ scores using the first measured value of the day. Intervals for the most abnormal value of each variable were constructed on a scale from 0 to 4 so that a value of 0 represented essentially normal function and was associated with an ICU mortality rate of < 5%, whereas a value of 4 represented marked functional derangement and an ICU mortality rate of > or = 50%.",
                              "The APPS is a 9-point score that is calculated by measuring the age, PaO2/FIO2 ratio, and plateau pressure at 24 h after the patient is diagnosed with moderate to severe ARDS and counting each one to 1-3. Since many variables are not needed for calculations, clinicians can easily predict the in-hospital mortality of mechanically ventilated patients with moderate to severe ARDS patients at bedside."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The death rate of children",
                              "Marshall Multiple Organ Dysfunction Score",
                              "the APPS score"
                        ],
                        "NCTId": [
                              "NCT04850469"
                        ]
                  },
                  {
                        "Rank": 56,
                        "OverallOfficialName": [
                              "Vrisha Madhuri, MS Orth"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)/Serious AE (SAE)/Suspected Unexpected Serious Adverse Reaction (SUSAR)with specific focus on the following:\n\nVital signs in conjunction with the MSC infusion\nTransfusion reactions (infusion toxicity, embolism, allergy, infections)\nImmune reaction towards the cells, donor-specific antibodies, graft rejection, Graft versus Host Disease, autoimmunity)\nTumourigenicity\nMortality/morbidity"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)"
                        ],
                        "NCTId": [
                              "NCT04623606"
                        ]
                  },
                  {
                        "Rank": 57,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Survival Rate"
                        ],
                        "NCTId": [
                              "NCT04247945"
                        ]
                  },
                  {
                        "Rank": 58,
                        "OverallOfficialName": [
                              "Jolanda Neele"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 28, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "OR is defined as complete response (CR) or partial response (PR) at Day 28 relative to aGvHD status at baseline. CR is defined as resolution of aGvHD in all involved organs. PR is defined as improvement in 1 stage in 1 or more organs involved with aGvHD symptoms without progression in others. Number of participants with OR will be reported."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Overall Response (OR)"
                        ],
                        "NCTId": [
                              "NCT04629833"
                        ]
                  },
                  {
                        "Rank": 59,
                        "OverallOfficialName": [
                              "Mary C. Territo, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation"
                        ],
                        "NCTId": [
                              "NCT00081055"
                        ]
                  },
                  {
                        "Rank": 60,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To investigate the relationship between the percentage of myeloid derived suppressive cells (MDSCs) in total leukocytes in peripheral blood and the relapse incidence after allogeneic stem cell transplantation.\n\nThe patients will be grouped according to median MDSC frequency values. Relapse incidence will be compared across the two groups (low and high frequency of MDSC)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Myeloid suppressive cells and relapse incidence"
                        ],
                        "NCTId": [
                              "NCT03964922"
                        ]
                  }
            ]
      }
}